Invokamet Tablet, Film Coated
Product Images NDC 50458-540

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Invokamet (NDC 50458-540). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Invokamet 01)

Chemical structure diagram depicting the active ingredient canagliflozin, as part of the product INVOKAMET, showing its molecular framework including rings, hydroxyl groups, and attached fluorophenyl and thienyl groups, with a notation of half water of hydration (1/2 H2O).*

FDA Label Image

Chemical Structure (Invokamet 02)

Chemical structure diagram depicting metformin hydrochloride, a component of the pharmaceutical product INVOKAMET. The structure shows a biguanide group with two methyl substitutions and a hydrochloride ion (HCl).*

FDA Label Image

Figure 1 (Invokamet 03)

A line graph illustrating the least squares mean change in HbA1c (%) from baseline over 52 weeks, comparing treatment effects of canagliflozin 100 mg, canagliflozin 300 mg, and glimepiride. The x-axis shows study weeks, and the y-axis shows the change in HbA1c. Data points indicate HbA1c reduction trends with standard error bars for each treatment group over time.*

FDA Label Image

Figure 2 (Invokamet 04)

A line graph comparing the least squares mean change in HbA1c percentage from baseline over a 52-week study period between Canagliflozin 300 mg and Sitagliptin 100 mg. The x-axis represents study weeks, and the y-axis represents LS mean change in HbA1c with standard error bars. Canagliflozin shows a slightly greater and more sustained reduction compared to Sitagliptin over time.*

FDA Label Image

Figure 3 (Invokamet 05)

A Kaplan-Meier curve comparing percentage of subjects with events over time (weeks) between canagliflozin (dashed line) and placebo (solid line) treatment groups. The graph includes a hazard ratio with 95% confidence interval (HR 0.86, 95% CI 0.75-0.97) and a table below showing the number of subjects at risk at various time points for each group.*

FDA Label Image

Figure 4 (Invokamet 06)

A Kaplan-Meier survival curve showing the percentage of subjects with events over time (weeks) comparing Cana (canagliflozin) versus Placebo. The Y-axis represents the percentage of subjects with events, and the X-axis represents time in weeks, up to approximately 182 weeks. Two lines illustrate the difference in event rates, with Cana consistently below Placebo. A table below the graph displays the number of subjects at risk at various time points for both groups. The hazard ratio (HR) with 95% confidence interval is noted as 0.70 (0.59, 0.82).*

FDA Label Image

Principal Display Panel (50 mg/500 mg Tablet Bottle Label)

Packaging label for Invokamet tablets containing canagliflozin and metformin hydrochloride, 50 mg/500 mg strength. The label indicates a count of 60 film-coated oral tablets supplied by Janssen Pharmaceuticals, Inc. It includes storage instructions and dispensing information, along with the NDC number 50458-540-60.*

FDA Label Image

Principal Display Panel (50 mg/1,000 mg Tablet Bottle Label)

Label for INVOKAMET tablets containing canagliflozin and metformin hydrochloride, strength 50 mg/1000 mg. The oral film-coated tablets are packaged in a container of 60 tablets by Janssen Pharmaceuticals, Inc. The label includes storage instructions, dispensing guidelines, and a barcode with NDC 50458-541-60.*

FDA Label Image

Principal Display Panel (150 mg/500 mg Tablet Bottle Label)

The image shows a label for INVOKAMET tablets containing canagliflozin and metformin hydrochloride. It specifies a strength of 150 mg/500 mg per tablet and a package size of 60 tablets. The label includes usage instructions such as storing in the original container and mentions the medication guide. Janssen Pharmaceuticals, Inc. is identified as the labeler, with the NDC 50458-542-60.*

FDA Label Image

Principal Display Panel (150 mg/1,000 mg Tablet Bottle Label)

Label for Invokamet tablets containing canagliflozin and metformin hydrochloride, strength 150 mg/1,000 mg. The label indicates a 60-tablet count and includes storage and dispensing instructions. The manufacturer is Janssen Pharmaceuticals, Inc. The label features the NDC 50458-543-60 and Rx only designation.*

FDA Label Image

Principal Display Panel (50 mg/500 mg Tablet Bottle Label)

Label for Invokamet XR 50 mg/500 mg extended-release tablets contains canagliflozin and metformin HCl. The package holds 60 film-coated tablets. The label includes storage instructions, dispensing guidelines, and manufacturer information from Janssen Pharmaceuticals, Inc. The product is prescription-only.*

FDA Label Image

Principal Display Panel (50 mg/1000 mg Tablet Bottle Label)

Label for Invokamet XR 50 mg/1000 mg extended-release tablets containing canagliflozin and metformin hydrochloride. The label specifies a 60-tablet package, with instructions to dispense with Medication Guide, store in the original container, and may be stored in a pill box for up to 30 days. Labeler is Janssen Pharmaceuticals, Inc.*

FDA Label Image

Principal Display Panel (150 mg/500 mg Tablet Bottle Label)

Package label for Invokamet XR tablets containing 150 mg canagliflozin and 500 mg metformin hydrochloride extended-release. The label indicates a 60-tablet count and instructs to dispense with the Medication Guide and store in the original container or a pill box for up to 30 days. Manufactured by Janssen Pharmaceuticals, Inc.*

FDA Label Image

Principal Display Panel (150 mg/1000 mg Tablet Bottle Label)

The image shows the packaging label for Invokamet XR 150 mg/1000 mg film-coated extended-release tablets, containing canagliflozin and metformin hydrochloride. The label indicates a 60-tablet count and is manufactured by Janssen Pharmaceuticals, Inc. Instructions include dispensing with a medication guide and storage recommendations, including that the tablets may be stored in a pill box for up to 30 days.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.